EGFR and non-small cell lung carcinoma: Moreover, in the FLAURA phase 3 clinical trial, progression-free survival and overall survival were longer with osimertinib than with first-generation TKIs and, therefore, in many countries, osimertinib has become the first-line standard of care for patients with EGFR-mutated non-small cell lung cancer (NSCLC) [3].